{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:05Z","timestamp":1769558405901,"version":"3.49.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To determine if tumor genetics are associated with overall survival (OS) after concurrent resection of colorectal liver metastases (CLM) and extrahepatic disease (EHD).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary Background Data:<\/jats:title>\n            <jats:p>The prognosis for patients who undergo concurrent resection of CLM\/EHD is unclear and the impact of somatic mutations has not been reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Patients undergoing concurrent resection of CLM and EHD from 2007 to 2017 were identified from 2 academic centers. From 1 center, patients were selected from a pre-existing database of patients undergoing cytore-ductive surgery with hyperthermic intraperitoneal chemotherapy. The Kaplan-Meier method was used to construct survival curves, compared using the log-rank test. Multivariable Cox analysis for OS was performed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>One hundred nine patients were included. Most common EHD sites included lung (33 patients), peritoneum (32), and portal lymph nodes (14). <jats:italic toggle=\"yes\">TP53<\/jats:italic> mutation was the most common mutation, identified in 75 patients (69%), and <jats:italic toggle=\"yes\">RAS\/TP53<\/jats:italic> co-mutation was identified in 31 patients (28%). The median OS was 49 months (interquartile range, 24\u2013125), and 3- and 5-year OS rates were 66% and 44%, respectively. Compared to patients without <jats:italic toggle=\"yes\">RAS\/ TP53<\/jats:italic> co-mutation, patients with <jats:italic toggle=\"yes\">RAS\/TP53<\/jats:italic> co-mutation had lower median OS: 39 vs. 51 months (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.02). On multivariable analysis, lung EHD [hazard ratio (HR), 0.7; 95% confidence intervals (CI), 0.3\u20131.4], peritoneal EHD (HR, 2.2; 95% CI, 1.1\u20134.2) and <jats:italic toggle=\"yes\">RAS\/TP53<\/jats:italic> co-mutation (HR, 2.8; 95% CI, 1.1\u20137.2) were independently associated with OS.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">RAS\/TP53<\/jats:italic> co-mutation is associated with worse OS after concurrent CLM\/EHD resection. Mutational status and site of EHD should be included in the evaluation of patients considered for concurrent resection.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/sla.0000000000004672","type":"journal-article","created":{"date-parts":[[2020,12,22]],"date-time":"2020-12-22T17:09:17Z","timestamp":1608656957000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["RAS\/TP53 Co-mutation is Associated With Worse Survival After Concurrent Resection of Colorectal Liver Metastases and Extrahepatic Disease"],"prefix":"10.1097","volume":"276","author":[{"given":"Heather A.","family":"Lillemoe","sequence":"first","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillaume","family":"Passot","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"},{"name":"EMR 3738, CICLY, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikuni","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"DeBellis","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, CHU Lyon Sud, Hospices Civils de Lyon, Pierre-B\u00e9nite, France"},{"name":"EMR 3738, CICLY, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Shin","family":"Chun","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Aloia","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Lopez","sequence":"additional","affiliation":[{"name":"Cancer Research Center of Lyon, Universit\u00e9 de Lyon, Universit\u00e9 Claude Bernard Lyon 1, Lyon, France; Department of Biochemistry and Molecular Biology, Lyon University Hospital, Hospices Civils de Lyon, Centre Hospitalier Lyon-Sud, Lyon, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Nicolas","family":"Vauthey","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,12,18]]},"reference":[{"key":"R1-20250424","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02552560","article-title":"Resection of the liver for colorectal carcinoma metastases. A multi-institutional study of long-term survivors","volume":"31","author":"Hughes","year":"1988","journal-title":"Dis Colon Rectum"},{"key":"R2-20250424","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00000658-199909000-00004","article-title":"Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases","volume":"230","author":"Fong","year":"1999","journal-title":"Ann Surg"},{"key":"R3-20250424","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S1072-7515(99)00089-7","article-title":"Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system","volume":"189","author":"Iwatsuki","year":"1999","journal-title":"JAm Coll Surg"},{"key":"R4-20250424","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1001\/archsurg.1997.01430290051008","article-title":"Hepatic resection for metastatic colorectal cancer results in cure for some patients","volume":"132","author":"Jamison","year":"1997","journal-title":"Arch Surg"},{"key":"R5-20250424","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/SLA.0b013e318207bf2c","article-title":"Concomitant extrahepatic disease in patients with colorectal liver metastases: when is there a place for surgery?","volume":"253","author":"Adam","year":"2011","journal-title":"Ann Surg"},{"key":"R6-20250424","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1245\/ASO.2005.01.010","article-title":"Hepatic and extrahepatic colorectal metastases: when resectable, their localization does not matter, but their total number has a prognostic effect","volume":"12","author":"Elias","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"R7-20250424","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/SLA.0000000000001624","article-title":"Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection","volume":"265","author":"Leung","year":"2017","journal-title":"Ann Surg"},{"key":"R8-20250424","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.hpb.2015.12.004","article-title":"Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes","volume":"18","author":"Hadden","year":"2016","journal-title":"HPB (Oxford)"},{"key":"R9-20250424","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1245\/s10434-017-6141-7","article-title":"Impact of RAS mutations in metastatic colorectal cancer after potentially curative resection: does site of metastases matter?","volume":"25","author":"Passot","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"R10-20250424","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/SLA.0000000000002319","article-title":"RAS mutation clinical risk score to predict survival after resection of colorectal liver metastases","volume":"269","author":"Brudvik","year":"2019","journal-title":"Ann Surg"},{"key":"R11-20250424","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11605-018-3890-y","article-title":"Surgical resection for recurrence after two-stage hepatectomy for colorectal liver metastases is feasible, is safe, and improves survival","volume":"23","author":"Lillemoe","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"R12-20250424","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1002\/cncr.28954","article-title":"KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases","volume":"120","author":"Kemeny","year":"2014","journal-title":"Cancer"},{"key":"R13-20250424","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11605-019-04399-3","article-title":"Innovation and future perspectives in the treatment of colorectal liver metastases","volume":"24","author":"Vauthey","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"R14-20250424","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/SLA.0000000000002450","article-title":"Deleterious effect of RAS and evolutionary high-risk TP53 double mutation in colorectal liver metastases","volume":"269","author":"Chun","year":"2019","journal-title":"Ann Surg"},{"key":"R15-20250424","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jamcollsurg.2019.04.027","article-title":"Conditional recurrence-free survival after resection of colorectal liver metastases: persistent deleterious association with RAS and TP53 co-mutation","volume":"229","author":"Kawaguchi","year":"2019","journal-title":"J Am Coll Surg"},{"key":"R16-20250424","doi-asserted-by":"crossref","first-page":"5843","DOI":"10.1158\/1078-0432.CCR-19-0863","article-title":"Mutation status of RAS, TP53, and SMAD4 is superior to mutation status of RAS alone for predicting prognosis after resection of colorectal liver metastases","volume":"25","author":"Kawaguchi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R17-20250424","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1158\/1078-0432.CCR-19-2390","article-title":"Coaltered Ras\/B-raf and TP53 is associated with extremes of survivorship and distinct patterns of metastasis in patients with metastatic colorectal cancer","volume":"26","author":"Datta","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R18-20250424","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1097\/SLA.0000000000001723","article-title":"A perioperative clinical pathway can dramatically reduce failure-to-rescue rates after cytoreductive surgery for peritoneal carcinomatosis: a retrospective study of 666 consecutive cytore-ductions","volume":"265","author":"Passot","year":"2017","journal-title":"Ann Surg"},{"key":"R19-20250424","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/136518202760378489","article-title":"The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000; 2:333\u201339","volume":"4","author":"Pang","year":"2002","journal-title":"HPB (Oxford)"},{"key":"R20-20250424","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"key":"R21-20250424","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.1200\/JCO.2011.38.2994","article-title":"Comparative genomic analysis of primary versus metastatic colorectal carcinomas","volume":"30","author":"Vakiani","year":"2012","journal-title":"J Clin Oncol"},{"key":"R22-20250424","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jmoldx.2013.05.003","article-title":"Clinical validation of a next-generation sequencing screen for mutational hotspots in 46 cancer-related genes","volume":"15","author":"Singh","year":"2013","journal-title":"J Mol Diagn"},{"key":"R24-20250424","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.suronc.2019.07.004","article-title":"Gene mutation and surgical technique: suggestion or more?","volume":"33","author":"Kawaguchi","year":"2019","journal-title":"Surg Oncol"},{"key":"R25-20250424","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1245\/s10434-010-1459-4","article-title":"Liver resection for colorectal metastases in presence of extrahepatic disease: results from an international multi-institutional analysis","volume":"18","author":"Pulitan\u00f2","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"R26-20250424","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1245\/s10434-009-0521-6","article-title":"Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center","volume":"16","author":"Carpizo","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"R27-20250424","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1245\/s10434-014-4207-3","article-title":"Is complete liver resection without resection of synchronous lung metastases justified?","volume":"22","author":"Mise","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"R28-20250424","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/DCR.0b013e318246b08d","article-title":"Factors influencing oncological outcomes in patients who develop pulmonary metastases after curative resection of colo-rectal cancer","volume":"55","author":"Kim","year":"2012","journal-title":"Dis Colon Rectum"},{"key":"R29-20250424","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jamcollsurg.2009.09.032","article-title":"Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer","volume":"210","author":"Maithel","year":"2010","journal-title":"J Am Coll Surg"},{"key":"R30-20250424","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/bjs.9783","article-title":"Surgical management of patients with colorectal cancer and simultaneous liver and lung metastases","volume":"102","author":"Andres","year":"2015","journal-title":"Br J Surg"},{"key":"R31-20250424","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/bjs.4071","article-title":"Extrahepatic disease does notcontrain-dicate hepatectomy for colorectal liver metastases","volume":"90","author":"Elias","year":"2003","journal-title":"Br J Surg"},{"key":"R32-20250424","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1245\/ASO.2004.03.085","article-title":"Results of R0 resection for colorectal liver metastases associated with extrahepatic disease","volume":"11","author":"Elias","year":"2004","journal-title":"Ann Surg Oncol"},{"key":"R33-20250424","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.surg.2008.02.004","article-title":"Prognostic value of concomitant resection of extrahepatic disease in patients with liver metastases of colorectal origin","volume":"143","author":"Aoki","year":"2008","journal-title":"Surgery"},{"issue":"18","key":"R34-20250424","doi-asserted-by":"crossref","first-page":"LBA3503","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA3503","article-title":"A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7","volume":"36","author":"Quenet","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Annals of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/SLA.0000000000004672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:00:41Z","timestamp":1745463641000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/SLA.0000000000004672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,18]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/sla.0000000000004672","relation":{},"ISSN":["0003-4932"],"issn-type":[{"value":"0003-4932","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,18]]}}}